SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Celldex Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.SCH’

On:  Monday, 2/26/24, at 7:05am ET   ·   For:  12/31/23   ·   Accession #:  1410578-24-76   ·   File #:  0-15006

Previous ‘10-K’:  ‘10-K’ on 2/28/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   31 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/24  Celldex Therapeutics, Inc.        10-K       12/31/23   87:8.5M                                   Toppan Merrill/FA2

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.24M 
 2: EX-1.1      Underwriting Agreement or Conflict Minerals Report  HTML    356K 
 3: EX-5.1      Opinion of Counsel re: Legality                     HTML     28K 
 4: EX-21.1     Subsidiaries List                                   HTML     25K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     24K 
 9: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     40K 
                Awarded Compensation                                             
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 8: EX-32       Certification -- §906 - SOA'02                      HTML     26K 
15: R1          Document and Entity Information                     HTML     96K 
16: R2          Consolidated Balance Sheets                         HTML    118K 
17: R3          Consolidated Balance Sheets (Parenthetical)         HTML     43K 
18: R4          Consolidated Statements of Operations and           HTML     96K 
                Comprehensive Loss                                               
19: R5          Consolidated Statements of Stockholders' Equity     HTML     67K 
20: R6          Consolidated Statements of Cash Flows               HTML     95K 
21: R7          Nature of Business and Overview                     HTML     28K 
22: R8          Summary of Significant Accounting Policies          HTML     63K 
23: R9          Accumulated Other Comprehensive Income              HTML     47K 
24: R10         Fair Value Measurements                             HTML     72K 
25: R11         Marketable Securities                               HTML    106K 
26: R12         Property and Equipment, Net                         HTML     45K 
27: R13         Leases                                              HTML     33K 
28: R14         Intangible Assets                                   HTML     26K 
29: R15         Accrued Expenses                                    HTML     39K 
30: R16         Other Long-Term Liabilities                         HTML     41K 
31: R17         Stockholders' Equity                                HTML     32K 
32: R18         Stock-Based Compensation                            HTML     83K 
33: R19         Revenue                                             HTML     29K 
34: R20         Collaboration Agreements                            HTML     27K 
35: R21         Income Taxes                                        HTML    111K 
36: R22         Retirement Savings Plan                             HTML     29K 
37: R23         Kolltan Acquisition                                 HTML     33K 
38: R24         Summary of Significant Accounting Policies          HTML    116K 
                (Policies)                                                       
39: R25         Summary of Significant Accounting Policies          HTML     32K 
                (Tables)                                                         
40: R26         Accumulated Other Comprehensive Income (Tables)     HTML     46K 
41: R27         Fair Value Measurements (Tables)                    HTML     69K 
42: R28         Marketable Securities (Tables)                      HTML    103K 
43: R29         Property and Equipment, Net (Tables)                HTML     43K 
44: R30         Leases (Tables)                                     HTML     31K 
45: R31         Accrued Expenses (Tables)                           HTML     38K 
46: R32         Other Long-Term Liabilities (Tables)                HTML     40K 
47: R33         Stock-Based Compensation (Tables)                   HTML     80K 
48: R34         Income Taxes (Tables)                               HTML    108K 
49: R35         Nature of Business and Overview (Details)           HTML     34K 
50: R36         Summary of Significant Accounting Policies - Basis  HTML     25K 
                of Presentation (Details)                                        
51: R37         Summary of Significant Accounting Policies -        HTML     32K 
                Concentration of Credit Risk and Significant                     
                Customers and Suppliers (Details)                                
52: R38         Summary of Significant Accounting Policies -        HTML     35K 
                Property and Equipment (Details)                                 
53: R39         Summary of Significant Accounting Policies -        HTML     33K 
                Leases (Details)                                                 
54: R40         Summary of Significant Accounting Policies -        HTML     26K 
                Foreign Currency Translation (Details)                           
55: R41         Summary of Significant Accounting Policies - Net    HTML     28K 
                Loss Per Share (Details)                                         
56: R42         Accumulated Other Comprehensive Income (Details)    HTML     48K 
57: R43         Fair Value Measurements (Details)                   HTML     33K 
58: R44         Fair Value Measurements - Additional information    HTML     50K 
                (Details)                                                        
59: R45         Marketable Securities (Details)                     HTML     64K 
60: R46         Marketable Securities - Additional Information      HTML     29K 
                (Details)                                                        
61: R47         Property and Equipment, Net (Details)               HTML     48K 
62: R48         Leases (Details)                                    HTML     49K 
63: R49         Leases - Future minimum lease payments under        HTML     33K 
                non-cancellable leases (Details)                                 
64: R50         Intangible Assets (Details)                         HTML     30K 
65: R51         Accrued Expenses (Details)                          HTML     34K 
66: R52         Other Long-Term Liabilities (Details)               HTML     37K 
67: R53         Other Long-Term Liabilities - Additional            HTML     34K 
                Information (Details)                                            
68: R54         Stockholders' Equity (Details)                      HTML     46K 
69: R55         Stock-Based Compensation - Employee Stock Purchase  HTML     44K 
                Plan (Details)                                                   
70: R56         Stock-Based Compensation - Employee Stock Option    HTML     64K 
                and Incentive Plan (Details)                                     
71: R57         Stock-Based Compensation - Stock Option Activity    HTML     69K 
                (Details)                                                        
72: R58         Stock-Based Compensation - Expenses (Details)       HTML     30K 
73: R59         Stock-Based Compensation - Valuation (Details)      HTML     46K 
74: R60         Revenue (Details)                                   HTML     42K 
75: R61         Collaboration Agreements (Details)                  HTML     31K 
76: R62         Income Taxes - Benefit (Provision) (Details)        HTML     38K 
77: R63         Income Taxes - Reconciliation (Details)             HTML     48K 
78: R64         Income Taxes - Summary of deferred tax assets and   HTML     49K 
                liabilities (Details)                                            
79: R65         Income Taxes - Carryforwards (Details)              HTML     45K 
80: R66         Retirement Savings Plan (Details)                   HTML     31K 
81: R67         Kolltan Acquisition (Details)                       HTML     45K 
82: R68         Insider Trading Arrangements                        HTML     29K 
84: XML         IDEA XML File -- Filing Summary                      XML    151K 
87: XML         XBRL Instance -- cldx-20231231x10k_htm               XML   1.54M 
83: EXCEL       IDEA Workbook of Financial Report Info              XLSX    132K 
11: EX-101.CAL  XBRL Calculations -- cldx-20231231_cal               XML    166K 
12: EX-101.DEF  XBRL Definitions -- cldx-20231231_def                XML    491K 
13: EX-101.LAB  XBRL Labels -- cldx-20231231_lab                     XML   1.21M 
14: EX-101.PRE  XBRL Presentations -- cldx-20231231_pre              XML    838K 
10: EX-101.SCH  XBRL Schema -- cldx-20231231                         XSD    150K 
85: JSON        XBRL Instance as JSON Data -- MetaLinks              482±   733K 
86: ZIP         XBRL Zipped Folder -- 0001410578-24-000076-xbrl      Zip    531K

‘EX-101.SCH’   —   XBRL Schema — cldx-20231231

This Exhibit is an XBRL File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL document created with Toppan Merrill Bridge 10.5.0.8 -->
<!-- Based on XBRL 2.1 -->
<!-- Created on: 2/26/2024 11:06:07 AM -->
<!-- Modified on: 2/26/2024 11:06:07 AM -->
<xsd:schema targetNamespace="http://www.celldextherapeutics.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cldx="http://www.celldextherapeutics.com/20231231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
<xsd:annotation>
<xsd:appinfo>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
<link:definition> 99900 - Disclosure - Standard And Custom Axis Domain Defaults </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
<link:definition> 00100 - Statement - CONSOLIDATED BALANCE SHEETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition> 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
<link:definition> 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
<link:definition> 40401 - Disclosure - Fair Value Measurements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesDetails">
<link:definition> 40501 - Disclosure - Marketable Securities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
<link:definition> 40601 - Disclosure - Property and Equipment, Net (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails" id="DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetails">
<link:definition> 40702 - Disclosure - Leases - Future minimum lease payments under non-cancellable leases (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailsCalc2" id="DisclosureLeasesFutureMinimumLeasePaymentsUnderNonCancellableLeasesDetailsCalc2">
<link:definition> 40702 - Disclosure - Leases - Future minimum lease payments under non-cancellable leases (Details) (Calc 2) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
<link:definition> 40901 - Disclosure - Accrued Expenses (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" id="DisclosureOtherLongTermLiabilitiesDetails">
<link:definition> 41001 - Disclosure - Other Long-Term Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryDetailsCalc2" id="DisclosureIncomeTaxesSummaryDetailsCalc2">
<link:definition> 41501 - Disclosure - Income Taxes - Summary (Details) Calc2 </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
<link:definition> 41502 - Disclosure - Income Taxes - Reconciliation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition> 41503 - Disclosure - Income Taxes - Summary of deferred tax assets and liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
<link:definition> 00090 - Document - Document and Entity Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
<link:definition> 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
<link:definition> 00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskAndSignificantCustomersAndSuppliersDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskAndSignificantCustomersAndSuppliersDetails">
<link:definition> 40202 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk and Significant Customers and Suppliers (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
<link:definition> 40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails">
<link:definition> 40204 - Disclosure - Summary of Significant Accounting Policies - Leases (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails">
<link:definition> 40206 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Share (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails" id="DisclosureAccumulatedOtherComprehensiveIncomeDetails">
<link:definition> 40301 - Disclosure - Accumulated Other Comprehensive Income (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
<link:definition> 40402 - Disclosure - Fair Value Measurements - Additional information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
<link:definition> 40701 - Disclosure - Leases (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsDetails" id="DisclosureIntangibleAssetsDetails">
<link:definition> 40801 - Disclosure - Intangible Assets (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails" id="DisclosureOtherLongTermLiabilitiesAdditionalInformationDetails">
<link:definition> 41002 - Disclosure - Other Long-Term Liabilities - Additional Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
<link:definition> 41101 - Disclosure - Stockholders' Equity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" id="DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails">
<link:definition> 41201 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanDetails" id="DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanDetails">
<link:definition> 41202 - Disclosure - Stock-Based Compensation - Employee Stock Option and Incentive Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
<link:definition> 41203 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails" id="DisclosureStockBasedCompensationExpensesDetails">
<link:definition> 41204 - Disclosure - Stock-Based Compensation - Expenses (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails" id="DisclosureStockBasedCompensationValuationDetails">
<link:definition> 41205 - Disclosure - Stock-Based Compensation - Valuation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
<link:definition> 41301 - Disclosure - Revenue (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreementsDetails" id="DisclosureCollaborationAgreementsDetails">
<link:definition> 41401 - Disclosure - Collaboration Agreements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesCarryforwardsDetails" id="DisclosureIncomeTaxesCarryforwardsDetails">
<link:definition> 41504 - Disclosure - Income Taxes - Carryforwards (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails" id="DisclosureKolltanAcquisitionDetails">
<link:definition> 41701 - Disclosure - Kolltan Acquisition (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverview" id="DisclosureNatureOfBusinessAndOverview">
<link:definition> 10101 - Disclosure - Nature of Business and Overview </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
<link:definition> 10201 - Disclosure - Summary of Significant Accounting Policies </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncome" id="DisclosureAccumulatedOtherComprehensiveIncome">
<link:definition> 10301 - Disclosure - Accumulated Other Comprehensive Income </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
<link:definition> 10401 - Disclosure - Fair Value Measurements </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
<link:definition> 10501 - Disclosure - Marketable Securities </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
<link:definition> 10601 - Disclosure - Property and Equipment, Net </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureLeases" id="DisclosureLeases">
<link:definition> 10701 - Disclosure - Leases </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
<link:definition> 10801 - Disclosure - Intangible Assets </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
<link:definition> 10901 - Disclosure - Accrued Expenses </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" id="DisclosureOtherLongTermLiabilities">
<link:definition> 11001 - Disclosure - Other Long-Term Liabilities </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
<link:definition> 11101 - Disclosure - Stockholders' Equity </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
<link:definition> 11201 - Disclosure - Stock-Based Compensation </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenue" id="DisclosureRevenue">
<link:definition> 11301 - Disclosure - Revenue </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureCollaborationAgreements" id="DisclosureCollaborationAgreements">
<link:definition> 11401 - Disclosure - Collaboration Agreements </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
<link:definition> 11501 - Disclosure - Income Taxes </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlan" id="DisclosureRetirementSavingsPlan">
<link:definition> 11601 - Disclosure - Retirement Savings Plan </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisition" id="DisclosureKolltanAcquisition">
<link:definition> 11701 - Disclosure - Kolltan Acquisition </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition> 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
<link:definition> 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" id="DisclosureAccumulatedOtherComprehensiveIncomeTables">
<link:definition> 30303 - Disclosure - Accumulated Other Comprehensive Income (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
<link:definition> 30403 - Disclosure - Fair Value Measurements (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
<link:definition> 30503 - Disclosure - Marketable Securities (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
<link:definition> 30603 - Disclosure - Property and Equipment, Net (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
<link:definition> 30703 - Disclosure - Leases (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
<link:definition> 30903 - Disclosure - Accrued Expenses (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" id="DisclosureOtherLongTermLiabilitiesTables">
<link:definition> 31003 - Disclosure - Other Long-Term Liabilities (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
<link:definition> 31203 - Disclosure - Stock-Based Compensation (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
<link:definition> 31503 - Disclosure - Income Taxes (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureNatureOfBusinessAndOverviewDetails" id="DisclosureNatureOfBusinessAndOverviewDetails">
<link:definition> 40101 - Disclosure - Nature of Business and Overview (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationDetails">
<link:definition> 40201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationDetails">
<link:definition> 40205 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency Translation (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
<link:definition> 40502 - Disclosure - Marketable Securities - Additional Information (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesBenefitProvisionDetails" id="DisclosureIncomeTaxesBenefitProvisionDetails">
<link:definition> 41501 - Disclosure - Income Taxes - Benefit (Provision) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.celldextherapeutics.com/role/DisclosureRetirementSavingsPlanDetails" id="DisclosureRetirementSavingsPlanDetails">
<link:definition> 41601 - Disclosure - Retirement Savings Plan (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cldx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</xsd:appinfo>
</xsd:annotation>
<xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
<xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
<xsd:element id="cldx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisePriceAsPercentageOfFairMarketValueForHoldersOfMoreThanTenPercentOfVotingStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="cldx_AccruedResearchAndDevelopmentContractCostsCurrent" name="AccruedResearchAndDevelopmentContractCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="CollaborativeArrangementDisclosureAbstract" id="cldx_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_DeferredIncomeFromSaleOfTaxBenefits" name="DeferredIncomeFromSaleOfTaxBenefits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="PeriodForWhichBaseOfOperationsMustBeMaintained" id="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration"/>
<xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" id="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit"/>
<xsd:element name="AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" id="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" name="IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="cldx_ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" name="ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element name="IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" id="cldx_IncomeTaxExpenseBenefitBeforeChangeInValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration"/>
<xsd:element id="cldx_NewlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" name="NewlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="cldx_ProceedsFromSaleOfOperatingLossesAndTaxCredits" name="ProceedsFromSaleOfOperatingLossesAndTaxCredits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit"/>
<xsd:element id="cldx_RockefellerMember" name="RockefellerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_YaleUniversityMember" name="YaleUniversityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_OperatingLossCarryforwardsNotSubjectToExpiration" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit"/>
<xsd:element id="cldx_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_NationalInstituteOfHealthMember" name="NationalInstituteOfHealthMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_KolltanPharmaceuticalsMember" name="KolltanPharmaceuticalsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_ContingentMilestoneMember" name="ContingentMilestoneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element id="cldx_ContractAssetsAndLiabilitiesPolicyTextBlock" name="ContractAssetsAndLiabilitiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="cldx_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration"/>
<xsd:element id="cldx_CombinedRockefellerUniversityAndGileadSciencesMember" name="CombinedRockefellerUniversityAndGileadSciencesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration"/>
<xsd:element name="StockOptionAndIncentivePlan2008Member" id="cldx_StockOptionAndIncentivePlan2008Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="FairValueAssetsLevel1ToLevel2TransfersAmount1" id="cldx_FairValueAssetsLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="FairValueAssetsLevel2ToLevel1TransfersAmount1" id="cldx_FairValueAssetsLevel2ToLevel1TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit"/>
<xsd:element name="FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" id="cldx_FairValueLiabilitiesLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" id="cldx_FairValueLiabilitiesLevel2ToLevel1TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid" id="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable" id="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" id="cldx_DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="DeferredTaxAssetsLiabilitiesGross" id="cldx_DeferredTaxAssetsLiabilitiesGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit"/>
<xsd:element name="StockholdersEquityTable" id="cldx_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="StockholdersEquityLineItem" id="cldx_StockholdersEquityLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="OtherLongTermLiabilitiesTable" id="cldx_OtherLongTermLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="OtherLongTermLiabilitiesLineItem" id="cldx_OtherLongTermLiabilitiesLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="IncomeTaxesTable" id="cldx_IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="IncomeTaxesLineItem" id="cldx_IncomeTaxesLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="NumberOfInvestmentGradeMarketableSecuritiesConsideredToBeOtherThanTemporarilyImpaired" id="cldx_NumberOfInvestmentGradeMarketableSecuritiesConsideredToBeOtherThanTemporarilyImpaired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false"/>
<xsd:element name="OperatingLeaseRightOfUseAssetIncreaseThroughNewLeasesAndLeaseExtensions" id="cldx_OperatingLeaseRightOfUseAssetIncreaseThroughNewLeasesAndLeaseExtensions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="OperatingLeaseLiabilitiesIncreaseThroughNewLeasesAndLeaseExtensions" id="cldx_OperatingLeaseLiabilitiesIncreaseThroughNewLeasesAndLeaseExtensions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
<xsd:element name="TamProgramIprDMember" id="cldx_TamProgramIprDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="NewJerseyEconomicDevelopmentAuthorityMember" id="cldx_NewJerseyEconomicDevelopmentAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="SummaryOfSignificantAccountingPoliciesTable" id="cldx_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="SummaryOfSignificantAccountingPoliciesLineItems" id="cldx_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="ExpectedDividendPayments" id="cldx_ExpectedDividendPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit"/>
<xsd:element name="LicenseAgreementWithYaleMember" id="cldx_LicenseAgreementWithYaleMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="RockefellerUniversityMember" id="cldx_RockefellerUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true"/>
<xsd:element name="CashOutflowForMilestonePaymentsMadeUponSuccessfulCompletionOfClinicalTrial" id="cldx_CashOutflowForMilestonePaymentsMadeUponSuccessfulCompletionOfClinicalTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit"/>
</xsd:schema>

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/01/24  Celldex Therapeutics, Inc.        424B5                  2:415K                                   Toppan Merrill/FA
 2/28/24  Celldex Therapeutics, Inc.        424B5                  1:377K                                   Toppan Merrill/FA
 2/26/24  Celldex Therapeutics, Inc.        424B5                  2:352K                                   Toppan Merrill/FA

28 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/15/23  Celldex Therapeutics, Inc.        8-K:5,9     6/15/23   11:221K                                   Toppan Merrill/FA
 2/28/23  Celldex Therapeutics, Inc.        10-K       12/31/22   85:8.1M                                   Toppan Merrill/FA
11/09/22  Celldex Therapeutics, Inc.        10-Q        9/30/22   62:6.5M                                   Toppan Merrill/FA
 8/08/22  Celldex Therapeutics, Inc.        10-Q        6/30/22   60:5.5M                                   Toppan Merrill/FA
 7/18/22  Celldex Therapeutics, Inc.        8-K:1,9     7/15/22   11:257K                                   Toppan Merrill/FA
 7/01/21  Celldex Therapeutics, Inc.        8-K:5,9     7/01/21   11:770K                                   Toppan Merrill/FA
 6/17/21  Celldex Therapeutics, Inc.        8-K:5,9     6/17/21    6:319K                                   Toppan Merrill/FA
 8/06/20  Celldex Therapeutics, Inc.        10-Q        6/30/20   60:4.6M                                   Toppan Merrill/FA
 6/18/20  Celldex Therapeutics, Inc.        8-K:5,9     6/18/20    2:149K                                   Toppan Merrill/FA
 3/26/20  Celldex Therapeutics, Inc.        10-K       12/31/19   97:7.7M                                   Toppan Merrill-FA
 6/20/19  Celldex Therapeutics, Inc.        8-K:5,9     6/19/19    3:217K                                   Toppan Merrill/FA
 5/07/19  Celldex Therapeutics, Inc.        10-Q        3/31/19   66:4.6M                                   Toppan Merrill/FA
 2/08/19  Celldex Therapeutics, Inc.        8-K:3,5,9   2/08/19    4:1M                                     Toppan Merrill/FA
 8/08/18  Celldex Therapeutics, Inc.        10-Q        6/30/18   58:4.3M                                   Toppan Merrill/FA
11/01/16  Celldex Therapeutics, Inc.        8-K:1,3,8,911/01/16    3:3M                                     Toppan Merrill/FA
 2/25/16  Celldex Therapeutics, Inc.        10-K/A     12/31/15   77:8.7M                                   Toppan Merrill-FA
 8/10/15  Celldex Therapeutics, Inc.        10-Q        6/30/15   51:3.9M                                   Toppan Merrill/FA
 5/03/13  Celldex Therapeutics, Inc.        10-Q        3/31/13   53:6.3M                                   Toppan Merrill/FA
12/23/10  Celldex Therapeutics, Inc.        10-K/A     12/31/09   18:1.1M                                   Toppan Merrill/FA
 8/05/10  Celldex Therapeutics, Inc.        10-Q        6/30/10    5:1M                                     Toppan Merrill/FA
 3/12/10  Celldex Therapeutics, Inc.        10-K       12/31/09   16:4.2M                                   Toppan Merrill-FA
11/10/08  Celldex Therapeutics, Inc.        10-Q        9/30/08    5:1.1M                                   Toppan Merrill/FA
 3/11/08  Celldex Therapeutics, Inc.        8-K:2,3,5,8 3/06/08    4:107K                                   Toppan Merrill/FA
 3/16/06  Celldex Therapeutics, Inc.        10-K       12/31/05    7:2M                                     Toppan Merrill/FA
11/08/04  Celldex Therapeutics, Inc.        8-K:8,9    11/05/04    4:297K                                   Toppan Merrill-FA
 4/30/04  Celldex Therapeutics, Inc.        10-Q        3/31/04    8:1M                                     Toppan Merrill/FA
 5/10/02  Celldex Therapeutics, Inc.        10-Q        3/31/02    2:291K                                   Toppan Merrill/FA
 7/16/98  Celldex Therapeutics, Inc.        S-4                   13:949K                                   Merrill/Daniels/FA
↑Top
Filing Submission 0001410578-24-000076   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., May 12, 12:45:31.3am ET